Dr. True is a surgical pathologist with subspecialty expertise in GU pathology and research on the molecular biology of prostate cancer, focused on tissue biomarkers of prognosis (for patients on active surveillance) and of prediction of response to systemic therapy (for patients whose prostate cancer has progressed). He is also investigating the application of innovative methods of tissue research using laser microdissection for proteomics, quantum dot-based immunohistochemistry and the 3-dimensional structure of prostate cancer.